Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Sonrotoclax Plus Dexamethasone Generates Early Efficacy in R/R Myeloma

September 21st 2025, 10:00am

International Myeloma Society Annual Meeting

Sonrotoclax plus dexamethasone was well tolerated and produced early efficacy signals in relapsed/refractory multiple myeloma with t(11;14).

BKd Produces Robust Responses in Relapsed/Refractory Multiple Myeloma

September 20th 2025, 9:10pm

International Myeloma Society Annual Meeting

Belantamab mafodotin plus carfilzomib and dexamethasone was active in patients with relapsed/refractory multiple myeloma.

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma

September 20th 2025, 8:35pm

International Myeloma Society Annual Meeting

Belantamab mafodotin plus lenalidomide maintenance was active and had an expected safety profile in transplant-eligible, newly diagnosed myeloma.

Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma

September 20th 2025, 7:10pm

International Myeloma Society Annual Meeting

Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.

Dr Leleu on QOL Outcomes With SC Isatuximab Via On-Body Delivery in R/R Myeloma

September 20th 2025, 6:23pm

International Myeloma Society Annual Meeting

Xavier Leleu, MD, PhD, discusses the role of subcutaneous isatuximab delivered via an on-body delivery system in patients with relapsed/refractory multiple myeloma.

ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma

September 20th 2025, 5:47pm

International Myeloma Society Annual Meeting

Carfilzomib, lenalidomide, and dexamethasone after transplant improved PFS and OS in high-risk, newly diagnosed multiple myeloma.

Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma

September 20th 2025, 5:35pm

International Myeloma Society Annual Meeting

Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma

September 20th 2025, 5:15pm

International Myeloma Society Annual Meeting

Maintenance therapy with daratumumab plus lenalidomide led to higher MRD-negativity conversion rates vs lenalidomide alone in newly diagnosed myeloma.

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma

September 20th 2025, 3:27pm

International Myeloma Society Annual Meeting

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Linvoseltamab Yields Favorable Safety Profile and Antimyeloma Activity in High-Risk Smoldering Myeloma

September 19th 2025, 11:28pm

International Myeloma Society Annual Meeting

Linvoseltamab monotherapy generated responses and had a favorable safety profile with low rates of high-grade TEAEs in high-risk smoldering myeloma.

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma

September 19th 2025, 10:14pm

International Myeloma Society Annual Meeting

Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.

Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or -Deferred, Newly Diagnosed Myeloma

September 19th 2025, 9:35pm

International Myeloma Society Annual Meeting

The combination of daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.

Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma

September 19th 2025, 9:31pm

International Myeloma Society Annual Meeting

The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.

Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma

September 19th 2025, 9:10pm

International Myeloma Society Annual Meeting

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr Rodriguez-Otero on Data for Linvoseltamab in High-Risk Smoldering Myeloma

September 19th 2025, 8:41pm

International Myeloma Society Annual Meeting

Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.

Belantamab Mafodotin Triplet Yields Responses With Low Ocular Toxicity in Intermediate-Fit or Frail Newly Diagnosed Myeloma

September 19th 2025, 8:38pm

International Myeloma Society Annual Meeting

Belantamab mafodotin plus lenalidomide and dexamethasone induced CRs or better in over half of patients with newly diagnosed multiple myeloma.

Co-Infusion of Anti-GPRC5D/Anti-BCMA Therapies Is Feasible, Yields Durable Responses in R/R Multiple Myeloma

September 19th 2025, 7:10pm

International Myeloma Society Annual Meeting

Administering the anti-GPRC5D agent MCARH109 and anti-BCMA therapy MCARH125 in tandem was feasible and tolerable in relapsed/refractory multiple myeloma.

Eque-Cel Demonstrates Activity in R/R Multiple Myeloma

September 19th 2025, 5:30pm

International Myeloma Society Annual Meeting

Eque-cel was effective for the treatment of patients with relapsed/refractory multiple myeloma.

Arlo-Cel Demonstrates Tolerability, Efficacy in R/R Myeloma

September 19th 2025, 4:30pm

International Myeloma Society Annual Meeting

Arlo-cel given as a single infusion drove efficacy and was safe in relapsed/refractory multiple myeloma.

D-VRd Produces Favorable PROs and Safety Outcomes in MRD-Negative Newly Diagnosed Multiple Myeloma

September 19th 2025, 3:56pm

International Myeloma Society Annual Meeting

D-VRd led to favorable PRO outcomes in patients with newly diagnosed multiple myeloma who had MRD negativity after therapy.